ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors
First dual-specific PD-L1/PD-L2 antibody with killing function designed to treat the many immune-excluded cancers that are resistant to existing immunotherapies
Phase 1b will focus on tumors that are resistant to existing immunotherapy, which may include ovarian, colorectal, and triple negative breast cancers
Melior Is Selected as a Top 20 CRO by Pharma Tech Outlook
– Melior has cover appearance on this industry-leading magazine
– Melior is recognized for the combination of its attention to quality, culture and, innovative offering
VESTECK , Inc. is excited to announce that the U.S. Patent Application No. 17/841,373 Title: REMOTE SURGICAL SUTURE SYSTEM, has been allowed by the U.S. Patent and Trademark Office (USPTO)
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy